Reuters logo
BRIEF-Protalix Biotherapeutics reports 2016 full year results
March 16, 2017 / 12:29 PM / 8 months ago

BRIEF-Protalix Biotherapeutics reports 2016 full year results

March 16 (Reuters) - Protalix Biotherapeutics Inc

* Protalix Biotherapeutics reports 2016 full year results and provides corporate update

* Protalix Biotherapeutics - in 2018, if generate positive interim results from pegunigalsidase phase II trial, sees begin filing process for approval with EMA

* Protalix Biotherapeutics Inc - anticipate funds will be sufficient to fund our operations into 2019

* Protalix Biotherapeutics Inc - at December 31, 2016, Protalix had $63.3 million of cash and cash equivalents, compared to $76.4 million at December 31, 2015 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below